Periotherapia Co., Ltd. will exhibit at BioJapan 2026 and JHVS 2026, taking place from October 7 to 9, 2026.

Periotherapia is developing PT0101, an antibody therapy designed to overcome cancer treatment resistance by targeting the tumor microenvironment. During the event, information on our research and development programs and business activities, including PT0101, will be available at our booth in the JHVS 2026 Area (booth No. V-62).

Eiji Tahara, CEO; Kensei Sakata, Head of Clinical Development; and Ko Hasegawa, VP, Business Development, will attend BioJapan 2026 and engage in meetings and discussions with potential pharmaceutical partners, investors, research collaborators, and business partners.

Exhibition Details
– Event: BioJapan 2026
– Dates: October 7–9, 2026
– Booth: V-62, JHVS 2026 Area
– Attending BioJapan 2026:
  – Eiji Tahara, CEO
  – Kensei Sakata, Head of Clinical Development
  – Ko Hasegawa, VP, Business Development

To arrange a meeting during the event, please contact us through the BioJapan 2026 partnering system or through our corporate contact channel.

We look forward to meeting you at BioJapan 2026 and JHVS 2026.